2005年11月
Trastuzumab: updates and future issues
CANCER CHEMOTHERAPY AND PHARMACOLOGY
- ,
- ,
- ,
- ,
- 巻
- 56
- 号
- SUPPL. 7
- 開始ページ
- S94
- 終了ページ
- S99
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1007/s00280-005-0110-8
- 出版者・発行元
- SPRINGER
Trastuzumab has had an enormous impact on the clinical management of breast cancer: the survival of Her-2-positive metastatic breast cancer patients has improved significantly and tumor Her-2 status has been built into the decision-making tree for primary breast cancer patients. Several pioneering studies have shown that trastuzumab-combined chemotherapy elicits high levels of pathological complete response in the neoadjuvant setting. Currently, therefore, a more precise understanding of the mechanisms of therapeutic response is needed so that trastuzumab-based therapies can be optimized more individually. It might also be important to investigate, with greater depth, the interaction between the Her-axis and the hormone-axis. This short review describes and discusses these topics.
- リンク情報
- ID情報
-
- DOI : 10.1007/s00280-005-0110-8
- ISSN : 0344-5704
- Web of Science ID : WOS:000234424500015